Is there one reconstitution protocol for DSIP?

No. DSIP solution behavior depends on formulation, concentration, pH, container, temperature and the experimental system. A protocol-specific stability study is more reliable than a generalized interval.

What does a purity result establish for DSIP?

Chromatographic purity describes the measured sample composition under the reported method. It does not establish sterility, biological activity, clinical safety or suitability for human use.

What is the DSIP peptide?

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated from rabbit blood dialysate and characterized in 1977. Its name reflects the EEG effect observed in those animal experiments; it is not an approved drug, and Novanta supplies it for laboratory research only.

Has DSIP been tested in humans?

Human observations from the original era are described in the published reviews, but the literature is decades old and largely preclinical, and its own reviewers concluded that central questions remained open. No modern controlled-trial base establishes an outcome for DSIP.

DSIP Peptide Research & Testing

Molecular overview

DSIP (delta sleep-inducing peptide) is a nine-residue peptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and a molecular weight of 849. It was isolated from the extracorporeal dialysate of cerebral venous blood in rabbits and characterized in 1977; its name describes the EEG effect observed in those animal experiments rather than any approved medical use.

Only the pure alpha-aspartyl form of the sequence showed the reported activity in the original characterization work, in contrast to its beta-aspartyl isomer. That isomer sensitivity makes sequence and isomer identity a relevant analytical question for any DSIP research material.

Research pathways

The original animal work reported enhancement of delta and spindle EEG patterns after infusion, evaluated double-blind in dozens of rabbits against control peptides, sequence fragments and analogues. Reviews of the broader literature also describe reported effects on neurotransmitter levels, circadian and locomotor patterns and hormone levels, though which of these reflect direct mechanisms remains unresolved.

A U-shaped dose-response relationship was reported for DSIP across administration routes, and penetration of the blood-brain barrier in essentially intact form was described. A proposed mechanism involving modulation of adrenergic transmission was noted by reviewers but explicitly described as unestablished.

Published-research summary

The DSIP literature is predominantly preclinical and concentrated in the late 1970s and 1980s. The 1984 review by Graf and Kastin concluded that roughly 100 publications later, the major questions were still open: what the peptide's main functions are, whether it is genuinely a sleep factor, whether and how it occurs naturally, and how it exerts its reported activities.

The same reviewers updated the literature in 1986, describing further animal sleep effects and exploratory work toward therapeutic applications, while again stating that physiological functions and the proposed adrenergic mechanism remained to be established. No comparable modern controlled-trial base exists, so human outcomes cannot be inferred from this literature.

Analytical testing methodology

For a short, sequence-sensitive peptide like DSIP, identity confirmation by mass spectrometry and chromatographic purity by HPLC are the appropriate baseline checks. The original characterization showed that a single aspartate isomer difference changes reported activity — exactly the class of discrepancy identity testing is intended to catch.

No Novanta lot report is currently posted for this product, so this page does not imply a lot-specific purity result. Posted certificates for other compounds are available on the Test Reports page.

Storage and stability

DSIP's sequence contains tryptophan, an amino-acid side chain susceptible to oxidative degradation in solution. Keep lyophilized material sealed, dry, protected from light and at the storage conditions on its documentation, and treat any solution-state work as requiring protocol-specific stability validation.

There is no universal post-reconstitution interval for DSIP. The Research Water reference and the Reconstitution Chemistry article cover diluent selection and stability controls without supplying dosing or human-use instructions.

Reconstitution and solution-state variables

Research water reconstitution is not a universal protocol. Peptide sequence, charge, concentration, pH, ionic strength, excipients, container and temperature can each change solubility and solution stability. Researchers should use compound- and protocol-specific controls rather than transfer a preparation method from another molecule.

The Research Water reference explains bacteriostatic and sterile water specifications, contamination controls and post-reconstitution stability limits. The Reconstitution Chemistry article and calculator provide additional laboratory context; neither supplies dosing or human-use instructions.

Research Water reference Reconstitution chemistry Reconstitution calculator

Novanta lot documentation

Laboratory: ILS Laboratories
Lot: NRDSIP10-0021
HPLC result: 99.47%
Analysis date: 09/09/2026

Open gated COA

Research material

Product availability, vial size and purchasing information are kept separate from this scientific reference.

View research material

References

Research questions

Is there one reconstitution protocol for DSIP?: No. DSIP solution behavior depends on formulation, concentration, pH, container, temperature and the experimental system. A protocol-specific stability study is more reliable than a generalized interval.
What does a purity result establish for DSIP?: Chromatographic purity describes the measured sample composition under the reported method. It does not establish sterility, biological activity, clinical safety or suitability for human use.
What is the DSIP peptide?: DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide first isolated from rabbit blood dialysate and characterized in 1977. Its name reflects the EEG effect observed in those animal experiments; it is not an approved drug, and Novanta supplies it for laboratory research only.
Has DSIP been tested in humans?: Human observations from the original era are described in the published reviews, but the literature is decades old and largely preclinical, and its own reviewers concluded that central questions remained open. No modern controlled-trial base establishes an outcome for DSIP.

Research-use boundary

For laboratory and research use only. Not for human or veterinary consumption. This page summarizes published research and does not provide medical advice, dosing guidance, or evidence that preclinical observations translate to people.

DSIP research overview